Kelsie L Thu

Summary

Affiliation: British Columbia
Country: Canada

Publications

  1. doi request reprint Methylation analysis by DNA immunoprecipitation
    Kelsie L Thu
    Department of Cancer Genetics and Developmental Biology, British Columbia Cancer Research Centre, 675 West 10th Avenue, Vancouver, BC V5Z 1L3, Canada
    J Cell Physiol 222:522-31. 2010
  2. pmc Lung adenocarcinoma of never smokers and smokers harbor differential regions of genetic alteration and exhibit different levels of genomic instability
    Kelsie L Thu
    Department of Integrative Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada
    PLoS ONE 7:e33003. 2012
  3. pmc Genetic disruption of KEAP1/CUL3 E3 ubiquitin ligase complex components is a key mechanism of NF-kappaB pathway activation in lung cancer
    Kelsie L Thu
    Integrative Oncology Department, BC Cancer Research Centre, Vancouver, Canada
    J Thorac Oncol 6:1521-9. 2011
  4. doi request reprint miR-101 DNA copy loss is a prominent subtype specific event in lung cancer
    Kelsie L Thu
    BC Cancer Research Centre, Vancouver, British Columbia, Canada
    J Thorac Oncol 6:1594-8. 2011
  5. pmc Integrative genomic analyses identify BRF2 as a novel lineage-specific oncogene in lung squamous cell carcinoma
    William W Lockwood
    Department of Cancer Genetics and Developmental Biology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada
    PLoS Med 7:e1000315. 2010
  6. pmc Integrating the multiple dimensions of genomic and epigenomic landscapes of cancer
    Raj Chari
    Genetics Unit Department of Integrative Oncology, British Columbia Cancer Research Centre, Vancouver, BC, Canada
    Cancer Metastasis Rev 29:73-93. 2010
  7. pmc Integrative genomics identified RFC3 as an amplified candidate oncogene in esophageal adenocarcinoma
    William W Lockwood
    Integrative Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada
    Clin Cancer Res 18:1936-46. 2012
  8. pmc Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development
    William W Lockwood
    Department of Integrative Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada
    PLoS ONE 7:e37775. 2012
  9. pmc Genomic Deregulation of the E2F/Rb Pathway Leads to Activation of the Oncogene EZH2 in Small Cell Lung Cancer
    Bradley P Coe
    Integrative Oncology Department, BC Cancer Research Centre, Vancouver, Canada
    PLoS ONE 8:e71670. 2013
  10. pmc Translating cancer 'omics' to improved outcomes
    Emily A Vucic
    British Columbia Cancer Research Centre, Vancouver V5Z 1L3, Canada
    Genome Res 22:188-95. 2012

Detail Information

Publications12

  1. doi request reprint Methylation analysis by DNA immunoprecipitation
    Kelsie L Thu
    Department of Cancer Genetics and Developmental Biology, British Columbia Cancer Research Centre, 675 West 10th Avenue, Vancouver, BC V5Z 1L3, Canada
    J Cell Physiol 222:522-31. 2010
    ....
  2. pmc Lung adenocarcinoma of never smokers and smokers harbor differential regions of genetic alteration and exhibit different levels of genomic instability
    Kelsie L Thu
    Department of Integrative Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada
    PLoS ONE 7:e33003. 2012
    ..Collectively, our findings provide evidence that these lung tumors are globally and genetically different, which implies they are likely driven by distinct molecular mechanisms...
  3. pmc Genetic disruption of KEAP1/CUL3 E3 ubiquitin ligase complex components is a key mechanism of NF-kappaB pathway activation in lung cancer
    Kelsie L Thu
    Integrative Oncology Department, BC Cancer Research Centre, Vancouver, Canada
    J Thorac Oncol 6:1521-9. 2011
    ..We investigated complex component gene disruption as a novel genetic mechanism of NF-κB activation in non-small cell lung cancer...
  4. doi request reprint miR-101 DNA copy loss is a prominent subtype specific event in lung cancer
    Kelsie L Thu
    BC Cancer Research Centre, Vancouver, British Columbia, Canada
    J Thorac Oncol 6:1594-8. 2011
    ..miR-101 is encoded at two loci in the human genome: 1p31.3 (miR-101-1) and 9p24.1 (miR-101-2). We sought to investigate miR-101 locus-specific deletions and genomic loss in the major subtypes of lung cancer...
  5. pmc Integrative genomic analyses identify BRF2 as a novel lineage-specific oncogene in lung squamous cell carcinoma
    William W Lockwood
    Department of Cancer Genetics and Developmental Biology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada
    PLoS Med 7:e1000315. 2010
    ..Identification of the molecular differences between these tumor types will have a significant impact in designing novel therapies that can improve the treatment outcome...
  6. pmc Integrating the multiple dimensions of genomic and epigenomic landscapes of cancer
    Raj Chari
    Genetics Unit Department of Integrative Oncology, British Columbia Cancer Research Centre, Vancouver, BC, Canada
    Cancer Metastasis Rev 29:73-93. 2010
    ....
  7. pmc Integrative genomics identified RFC3 as an amplified candidate oncogene in esophageal adenocarcinoma
    William W Lockwood
    Integrative Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada
    Clin Cancer Res 18:1936-46. 2012
    ..We employed an integrative genomics approach to identify novel genes involved in EAC biology that may serve as useful clinical markers...
  8. pmc Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development
    William W Lockwood
    Department of Integrative Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada
    PLoS ONE 7:e37775. 2012
    ..Together, our findings suggest that AC and SqCC develop through distinct pathogenetic pathways that have significant implication in our approach to the clinical management of NSCLC...
  9. pmc Genomic Deregulation of the E2F/Rb Pathway Leads to Activation of the Oncogene EZH2 in Small Cell Lung Cancer
    Bradley P Coe
    Integrative Oncology Department, BC Cancer Research Centre, Vancouver, Canada
    PLoS ONE 8:e71670. 2013
    ..In conclusion, our data confirm the role of EZH2 as a critical oncogene in SCLC, and lend support to the prioritization of EZH2 as a potential therapeutic target in clinical disease. ..
  10. pmc Translating cancer 'omics' to improved outcomes
    Emily A Vucic
    British Columbia Cancer Research Centre, Vancouver V5Z 1L3, Canada
    Genome Res 22:188-95. 2012
    ..We focus on the unique advantages of a multidimensional approach to genomic analysis in this new high-throughput omics age and discuss the implications of the changing cancer demographic to translational omics research...
  11. pmc EZH2 promotes E2F-driven SCLC tumorigenesis through modulation of apoptosis and cell-cycle regulation
    Roland Hubaux
    Integrative Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada
    J Thorac Oncol 8:1102-6. 2013
    ..Given the therapeutic potential of EZH2 as a target, we sought to delineate the downstream consequences of EZH2 disruption to identify the cellular mechanisms by which EZH2 promotes tumorigenesis in SCLC...
  12. doi request reprint Copy number variations in the human genome and strategies for analysis
    Emily A Vucic
    Department of Cancer Genetics and Developmental Biology, British Columbia Cancer Research Centre, Vancouver, BC, Canada
    Methods Mol Biol 628:103-17. 2010
    ..In this article, we provide a detailed review of human genetic variations and the experimental approaches used to discover, catalog, and genotype CNVs...